Objective-Vascular calcification (VC) is an important predictor of cardiovascular morbidity and mortality. Osteogenic differentiation of vascular smooth muscle cells (VSMCs) is a key mechanism of VC. Recent studies show that IL-18 (interleukin-18) favors VC while TRPM7 (transient receptor potential melastatin 7) channel upregulation inhibits VC. However, the relationship between IL-18 and TRPM7 is unclear. We questioned whether IL-18 enhances VC and osteogenic differentiation of VSMCs through TRPM7 channel activation. Approach and Results-Coronary artery calcification and serum IL-18 were measured in patients by computed tomographic scanning and enzyme-linked immunosorbent assay, respectively. Primary rat VSMCs calcification were induced by high inorganic phosphate and exposed to IL-18. VSMCs were also treated with TRPM7 antagonist 2-aminoethoxy-diphenylborate or TRPM7 small interfering RNA to block TRPM7 channel activity and expression. TRPM7 currents were recorded by patch-clamp. Human studies showed that serum IL-18 levels were positively associated with coronary artery calcium scores (r=0.91; P<0.001). In VSMCs, IL-18 significantly decreased expression of contractile markers α-smooth muscle actin, smooth muscle 22 α, and increased calcium deposition, alkaline phosphatase activity, and expression of osteogenic differentiation markers bone morphogenetic protein-2, Runx2 (runt-related transcription factor 2), and osteocalcin (P<0.05). IL-18 increased TRPM7 expression through ERK1/2 (extracellular signal-regulated kinase 1/2) signaling activation, and TRPM7 currents were augmented by IL-18 treatment. Inhibition of TRPM7 channel by 2-aminoethoxy-diphenylborate or TRPM7 small interfering RNA prevented IL-18-enhanced osteogenic differentiation and VSMCs calcification. Conclusions-These findings suggest that coronary artery calcification is associated with increased IL-18 levels. enhances VSMCs osteogenic differentiation and subsequent VC induced by β-glycerophosphate via TRPM7 channel activation. Accordingly, IL-18 may contribute to VC in proinflammatory conditions. Visual Overview-An online visual overview is available for this article. failure, plasma IL-18 levels were elevated and considered as a strong predictor for poor outcomes of patients with chronic renal failure. 13, 14 Interestingly, recent studies showed that elevated plasma levels of IL-18 were significantly associated with VC in CKD stages 3 and 4 patients. 15 Accordingly, IL-18 might be involved in the process of VC, and the underlying mechanisms need to be further studied.
V ascular calcification (VC) is a pathological process that occurs in many diseases, such as hypertension, diabetes mellitus, and chronic kidney disease (CKD). 1 It directly correlates with an elevated risk of cardiovascular morbidity and mortality. 2, 3 Previously, VC was considered as an inevitable process because of passive precipitation of calcium and phosphate. VC is now thought to be a complex and actively regulated process sharing similarities with bone formation. 1, 4 Numerous risk factors, including hyperphosphatemia, have been implicated in VC. 5 Our recent study demonstrated that β-glycerophosphate stimulation of vascular smooth muscle cells (VSMCs) induced osteogenic differentiation and calcification. 6 Although the primary mechanism of VC is VSMCs transformation to osteo-/chondrocytic-like cells, 7, 8 underlying processes of VC remain elusive in proinflammatory conditions.
Inflammation plays a vital role in chronic renal failure and is associated with a high incidence of VC. 9 IL-18 (interleukin-18) is a proinflammatory cytokine that belongs to the IL-1 superfamily and is produced by macrophages and other cells, including VSMCs. 10, 11 IL-18 binds to its IL-18 receptor, and together with IL-12, induces cell-mediated immune inflammatory response. 12 Usually, IL-18 is activated by the inflammasome. Previous studies demonstrated that in chronic renal October 2017 failure, plasma IL-18 levels were elevated and considered as a strong predictor for poor outcomes of patients with chronic renal failure. 13, 14 Interestingly, recent studies showed that elevated plasma levels of IL-18 were significantly associated with VC in CKD stages 3 and 4 patients. 15 Accordingly, IL-18 might be involved in the process of VC, and the underlying mechanisms need to be further studied.
The TRPM7 (transient receptor potential melastatin 7) cation channel, a member of the TRP melastatin subfamily, is a Mg 2+ -and Ca
2+
-permeable ion channel covalently coupled to an α-type Ser/Thr protein kinase domain. TRPM7 has been found in VSMCs and plays an important role in the transdifferentiation of the VSMC phenotype. 16 , 17 Montezano et al 17 demonstrated that TRPM7 is critically involved in VSMCs differentiation to an osteogenic phenotype, a process that is regulated by magnesium. In another study, Zhang et al 18 showed that upregulation of TRPM7 channel by angiotensin II contributed to the development of a proliferative phenotype of aortic VSMCs. Similarly, Lin et al 19 showed that TRPM7 channel activation inhibited oxidized low-density lipoprotein-induced proliferation and migration of VSMCs via MEK-ERK (mitogen-activated protein kinase kinase-extracellular signal-regulated kinase) pathways. Thus, all these recent findings indicate that TRPM7 is a potential and important molecular regulator of VC. 17, 20 However, whether TRPM7 takes part in osteogenic differentiation and calcification of VSMCs enhanced by IL-18 has not been explored.
In the present study, we investigated whether IL-18 enhanced VC and osteogenic differentiation of VSMCs and explored the potential role of TRPM7 channel in this process.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Serum Levels of IL-18 Are Associated With VC in Humans
To evaluate the relationship between serum levels of IL-18 and VC, we assessed serum levels of IL-18 in different VC groups. Sixty-four participants entered into this study. The baseline characteristics were shown in the Table. Based on the coronary artery calcium scores, 5 groups were defined. We found that 41 (64%) participants had coronary artery calcification. Serum levels of IL-18 were progressively elevated with the increasing severity of VC ( Figure 1A ). Moreover, a Spearman correlation analysis showed that the serum IL-18 levels were significantly associated with the coronary artery calcium scores (r=0.91; P<0.001; Figure 1B ).
IL-18 Enhances VC in Cultured VSMCs
To evaluate whether IL-18 directly promotes VC, VSMCs were incubated in DMEM without β-glycerophosphate (β-GP) and treated with or without IL-18 for 14 days, respectively. The results showed no significant difference of Alizarin red S staining, calcium deposition, and alkaline phosphatase (ALP) activity, indicating no direct effect of IL-18 on VC (Figure 2A-2C) . We then exposed rat VSMCs to increasing concentrations of IL-18 in calcifying medium containing β-GP for 14 days. The calcium deposition and ALP activity were assessed to reflect VC. As shown in Figure 2D and 2E, 5 ng/mL IL-18 did not significantly influence calcium deposition and ALP activity of VSMCs (P>0.05). In contrast, calcium deposition and ALP activity of VSMCs were gradually enhanced by the supplementation with increasing concentrations (from 10 to 100 ng/mL) of IL-18 (P<0.01). These results indicated that IL-18 augmented VC in a dose-dependent manner. Furthermore, VSMCs were treated with 100 ng/mL IL-18 in the β-GP-calcifying medium for different time of treatment. IL-18 significantly enhanced calcium deposition and ALP activity at different stimulation time points compared with the group cultured without IL-18 (P<0.05; Figure 2F and 2G). These results suggest that IL-18 also enhanced VC in a time-dependent manner.
IL-18 Enhances Osteogenic Differentiation of VSMCs
We further test whether IL-18 enhances osteogenic differentiation of VSMCs. BMP2 (bone morphogenetic protein-2) is a wildly used marker for osteogenic differentiation of VSMCs. 21 First, we demonstrated that IL-18 alone did not influence the expression of BMP2 ( Figure 2H ). Then, we exposed rat VSMCs to increasing concentrations of IL-18 in calcifying medium containing β-GP for 14 days. As shown in Figure 2I and 2J, compared with the group cultured without IL-18, the mRNA and protein levels of BMP2 were increased in VSMCs stimulated with increasing IL-18 concentrations (from 10 to 100 ng/mL; P<0.01). However, no significant difference was found in VSMCs when treated with 5 ng/mL IL-18 (P>0.05). Primary rat VSMCs were also treated with 100 ng/mL IL-18 in the calcifying medium for different time periods, and results showed that IL-18 significantly enhanced the mRNA and protein levels of BMP2 at different stimulation time points (from 4 to 14 days) as compared with the group cultured without IL-18 (P<0.05; Figure 2K and 2L). Our findings demonstrated that IL-18 enhanced osteogenic differentiation of VSMCs both in a dose-dependent and time-dependent manner.
IL-18 Upregulates Expression of TRPM7 in Calcifying VSMCs
We then investigate whether IL-18 affects TRPM7 expression in calcifying VSMCs. Immunofluorescence analysis showed that TRPM7 expression was significantly increased in the calcifying 
IL-18 Activates TRPM7 Currents in Calcifying VSMCs
To evaluate the effect of IL-18 on TRPM7 currents, we performed patch-clamp studies to examine TRPM7 currents. 
Inhibition of TRPM7 Ameliorates VC Enhanced by IL-18
To evaluate whether Inhibition of TRPM7 ameliorates VC enhanced by IL-18, we inhibited TRPM7 channel by using a TRPM7 antagonist, 2-aminoethoxy-diphenylborate (2-APB), and TRPM7 gene knock down by small interfering (si)RNA. Compared with scrambled siRNA, TRPM7 siRNA significantly reduced expression of TRPM7, indicating efficiency of the system ( Figure 4C ). Histologically, we demonstrated that TRPM7 silencing did not cause detectable spontaneous VSMCs calcification after 14 days culture in the absence of calcifying medium ( Figure I in the online-only Data Supplement). When exposed to calcifying medium, both TRPM7 siRNA and TRPM7 inhibitor 2-APB ameliorated calcification deposition and decreased ALP activity of VSMCs ( 
Inhibition of TRPM7 Attenuates IL-18-Enhanced Osteogenic Differentiation of VSMCs
We then determine whether inhibition of TRPM7 suppresses IL-18-stimulated osteogenic differentiation of VSMCs. First, we demonstrated that TRPM7 silencing did effectively 
All values are expressed as mean±SD. BMI indicates body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; and UA, uric acid. According to the coronary artery calcium scores, the degree of VC was divided: 0 (no calcification), 1 to <10 (minimal calcification), 10 to 100 (mild calcification), 101 to 300 (moderate calcification), and >300 (extensive calcification). We found that the serum levels of IL-18 were gradually increased accompanied with severity of VC. *P<0.05 vs no calcification group; #P<0.05 vs minimal calcification group; &P<0.05 vs mild calcification group; @P<0.05 vs moderate calcification group. B, A Spearman correlation analysis showed that the serum levels of IL-18 were significantly associated with the coronary artery calcium scores (r=0.91; P<0.001).
inhibited osteogenic differentiation of VSMCs after 14 days culture in the calcifying medium and IL-18 ( Figure II in the online-only Data Supplement). Then, the flow cytometry results showed that the expression of contractile markers of VSMCs, α-smooth muscle actin and smooth muscle 22 α, was significantly decreased by β-GP (α-smooth muscle actin, from 93.4% to 60.4%; smooth muscle 22 α, from 87.2% to 63.6%), and IL-18 further decreased the expression (α-smooth muscle actin, from 60.4% to 37.9%; smooth muscle 22 α, from 63.6% to 27%; P<0.05; Figure 5A -5C).
However, when treated with 2-APB or TRPM7 siRNA, the percentage of α-smooth muscle actin and smooth muscle 22 α was elevated ( Figure 5A-5C ). Moreover, expression of the osteogenic markers BMP2, Runx2 (runt-related transcription factor 2), and osteocalcin were induced by β-GP and further enhanced by IL-18 (P<0.05; Figure 5D -5F). 2-APB and TRPM7 siRNA significantly prevented the IL-18-enhanced osteogenic differentiation processes (P<0.05; Figure 5D -5F). The same findings were also demonstrated by Western blot analysis (Figure 5G-5L) . Interestingly, we found from the Western results that 2-APB and TRPM7 siRNA, especially TRPM7 siRNA, mainly inhibited osteogenic differentiation of VSMCs under the calcified condition treated with IL-18 ( Figure 5G-5L) .
Inhibition of TRPM7 Decreases IL-18-Stimulated TRPM7 Channel Currents of VSMCs
Both 2-APB and TRPM7 siRNA attenuated TRPM7 channel currents in VSMCs cultured with calcifying medium (P<0.05; Figure 6A and 6B). Furthermore, in calcifying VSMCs treated with IL-18, the TRPM7 channel currents were also decreased by 2-APB and TRPM7 siRNA (P<0.05; Figure 6C and 6D).
ERK Signaling Is Involved in the Process of IL-18-Enhanced TRPM7 Expression
We have demonstrated that IL-18 enhanced TRPM7 expression ( Figure 3) . To explore the potential role of ERK signaling in IL-18-enhanced TRPM7, we evaluated the expression of p-ERK and total ERK. The results showed that the ratio of p-ERK/total ERK was increased by β-GP and further elevated by IL-18 (P<0.05; Figure 6 E). However, this effect was blocked by ERK1/2 inhibitor U0126 ( Figure 6E ). Moreover, we found that U0126 decreased IL-18-enhanced TRPM7 expression, while 2-APB and TRPM7 siRNA had no effect on the ratio of p-ERK/total ERK ( Figure 6F and 6G). These findings indicate that IL-18 enhanced TRPM7 expression via ERK1/2 signaling activation.
Discussion
The main findings of our study demonstrate that IL-18 is associated with VC in humans and that it enhances VC and osteogenic differentiation of VSMCs through processes that involve TRPM7 channel activation.
VC is a dynamic and actively regulated process influenced by various factors, including inflammatory mediators. 22 Recent findings demonstrated that IL-18 is associated with VC in patients with CKD, 15, 23 where a decrease in glomerular filtration rate is accompanied with a rise in IL-18 levels. Furthermore, CKD patients with higher concentrations of IL-18 had higher hospitalization rates and higher cardiovascular morbidity and mortality. [24] [25] [26] Valente et al 27 found that in vitro IL-18 induced cardiac fibrosis migration and differentiation through cytoplasmic adapter protein TRAF3IP2. In another study, Harrison et al 28 found that epithelial-derived IL-18 regulated Th17 (T-helper 17) cell differentiation. Their conclusions support the notion that IL-18 plays a key role in cell differentiation. In this study, we evaluated osteogenic differentiation of VSMCs by detecting the main osteogenic marker BMP2. Although upregulation of BMP2 is demonstrated to promote calcification, the crucial mechanism of calcification is still unclear. Interestingly, our findings showed that IL-18 alone has no direct effect on VC and BMP2 expression. However, under calcifying condition, the procalcific effect of IL-18 and accelerating osteogenic differentiation of VSMCs were greatly activated. And such processes mainly involved in TRPM7 channel activation. It indicates that IL-18 plays procalcific effect and accelerates osteogenic differentiation of VSMCs should under calcified condition.
Increased pulse wave velocity is an independent risk of cardiovascular morbidity and mortality among patients with CKD 29 and is an effective indicator of arterial stiffness and VC. 30 Porazko et al 23 first reported that IL-18 was positively correlated with pulse wave velocity. However, whether IL-18 directly enhances VC has not been explored before.
In this study, we demonstrated for the first time that IL-18 directly enhanced VC and osteogenic differentiation of VSMCs. In the present study, we unravel some novel mechanisms through TRPM7 in IL-18-mediated VC. Previous studies suggested that IL-18 accelerated arterial injury in CKD through the induction of lymphocyte differentiation to Th-1 cells which express IL-18 receptor. 31 However, this hypothesis has not been confirmed because other findings demonstrated that the effect of IL-18 was mainly on atherosclerosis. 32, 33 Recent studies have shown that the pathological process of VC is different from atherosclerosis. The bone-vascular axis is an important mechanism of VC. 34 Lowering serum levels of low-density lipoprotein cholesterol by statins, the most effective method for suppressing atherosclerosis among lipid-lowering treatments, did not attenuate the progression of VC. 35 More importantly, recent studies found that statins promoted VC independent of their plaque-regressive effects. 36 In the present study, we have further investigated putative mechanisms of VC, focusing on IL-18 and TRPM7.
Accumulating evidence suggests that VC is a process similar to bone formation. 1, 4 TRPM7, a Mg
2+
-and Ca
-permeable ion channel, has been found to be involved in the proliferation and migration of human osteoblasts. 37 Interestingly, recent studies also demonstrated that TRPM7 is a regulator of VSMCs differentiation 17, 20 and that it plays a role in angiotensin II-induced hypertension. 38 Our data showed that the mRNA/protein levels and the currents of TRPM7 were significantly increased in calcifying VSMCs, which were further enhanced by IL-18. These effects were inhibited by TRPM7 inhibitor 2-APB and TRPM7 siRNA. Furthermore, we found that inhibition of TRPM7 attenuated osteogenic differentiation of VSMCs induced by β-GP and enhanced by IL-18. Our findings indicated that TRPM7 channel activation was involved in the process of VC and osteogenic differentiation of VSMCs induced by β-GP and enhanced by IL-18.
TRPM7 is a member of the TRP melastatin subfamily that mediates capacitative Ca 2+ and Mg 2+ entry into the cells. TRPM7 combines structural elements of both an ion channel and a protein kinase. 39 Through Ca 2+ and Mg 2+ signals, TRPM7 channels participate in many physiological and pathological processes, such as hypertension, atrial fibrillation, cancer, and ischemic stroke. 40, 41 A series of factors have been found to regulate TRPM7 channels, including Mg 2+ or Mg-ATP, extracellular pH, angiotensin II, and bradykinin. 16, 40, 42 Among these factors, Mg 2+ is the most important regulator. Montezano et al identified that the transporter activity of TRPM7 was decreased by calcifying medium containing a high-normal (3.0 mmol/L) level of magnesium. 17 In that study, TRPM7 was considered to play a protective role in VC, which is in contrast to our study. Louvet et al 20 also showed in their study that inhibition of TRPM7 led to the inefficiency of Mg 2+ (1.5 and 2 mmol/L) to prevent VC. However, the concentration of magnesium exogenously added in those and other studies was higher than the values observed in patients taking Mg-based phosphate binders. 43, 44 It is known that physiological concentration of Mg 2+ is 0.8 to 1.0 mmol/L, and in apparently healthy Western people, the concentration of Mg 2+ even ranges between 0.6 and 0.7 mmol/L. 45 Under many pathological conditions, such as hypertension, heart failure, and atherosclerosis, patients are prone to magnesium deficiency. 46 And in these important pathologies, TRPM7 channels are often activated. 19 It is shown that magnesium deficiency is associated with IL-18 enhancement in insulin resistance. 47 So, we presume that in the process of IL-18 enhanced VC, extracellular Mg 2+ may decrease, and TRPM7 expression compensatory increase. However, we did not measure the concentration of extracellular Mg 2+ , and this hypothesis needs further demonstration. 43 , 44 Moreover, we found that TRPM7 siRNA is more effectively inhibited osteogenic differentiation of VSMCs than 2-APB especially under the calcified condition treated with IL-18. This implies that inhibiting TRPM7 expression maybe more important than inhibiting its activity. Or it indicates that 2-APB, the nonspecific inhibitor of TRPM7, not effectively for inhibiting osteogenic differentiation. Other specific TRPM7 inhibitors are needed to verify our findings.
ERK1/2 signaling is involved in regulating VSMC function, including proliferation, cell survival, inflammation, and apoptosis in response to diverse stimuli. 48 Zhang et al 18 demonstrated that angiotensin II induced increased expression of TRPM7 in VSMCs and that this effect was required for ERK1/2 signaling. In another study, Lin et al 19 demonstrated that TRPM7 channel regulated oxidized low-density lipoprotein-induced proliferation and migration of VSMCs via MEK-ERK pathways. However, whether ERK1/2 signaling is involved in the process of IL-18 enhanced TRPM7 activation in VC has not been explored. It has been shown that IL-18 plays a role in ERK1/2 pathway. 49 In our study, we found that IL-18 activated ERK1/2 signaling during the process of VC and osteogenic differentiation accompanied with TRPM7 activation. Using the ERK1/2 signaling inhibitor U0126 significantly decreased IL-18-enhanced TRPM7 expression. Hence, our findings showed that IL-18 influenced TRPM7 channel activation and subsequently accelerated VC by activating ERK1/2 signaling. However, further clarification is needed.
In summary, we demonstrate that IL-18 enhances VC and osteogenic differentiation of VSMCs induced by β-GP through TRPM7 activation. IL-18 alone had no direct effect on VC and osteogenic differentiation of VSMCs. We also found that IL-18 enhanced TRPM7 expression via ERK1/2 signaling activation.
